Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UI-102 in Advanced Solid Tumors
NCT07605962Phase 2Recruiting
- Sponsor
- United Immunity Co., Ltd.
- Start
- May 2026
- Primary completion
- Mar 2030
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of UI-102 in solid tumor, sponsored by United Immunity Co., Ltd.. Started May 2026; status: recruiting.
02
Drugs
UI-102
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07605962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605962.